Finch Therapeutics Group, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Finch Therapeutics Group, Inc. | FNCH - NASDAQ |
$15.00-$17.00 | $17.00 | $20.45 | 7.5 million | 3/19/2021 |
| BofA Securities, Jefferies, Evercore ISI | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2021-02-26 Terms Added 2021-03-15 | ||||||
Finch Therapeutics Group, Inc. Quote & Chart - Click for current quote - FNCH
IPO Boutique aggregates information on public companies and private companies, such as "FNCH" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Finch Therapeutics Group, Inc. (adapted from Finch Therapeutics Group, Inc. prospectus):
They are a clinical-stage microbiome therapeutics company leveraging our Human-First Discovery platform to develop a novel class of orally administered biological drugs.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage microbiome therapeutics company leveraging our Human-First Discovery platform to develop a novel class of orally administered biological drugs.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "FNCH" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.